MEN1 and acute myeloid leukemia: In addition, we find this same GMP-like program is upregulated in a previously characterized menin-inhibitor-resistant AML, suggesting the persistent activation of this GMP-like program may be a recurring mechanism of epigenetic resistance that allows MLLr leukemias to evade targeted therapies.